Rapid reversal of innate immune dysregulation in blood of patients and livers of humanized mice with HCV following DAA therapy (original) (raw)
Fig 3
Differential transcriptional changes are associated with IFN-free DAA therapy and IFN/Ribavirin therapy.
(A) Representation of the shared and different transcriptional changes in DAA therapy (EOT) compared to IFNα/Ribavirin therapy (wk 10) (19). The top 1000 genes statistically significantly changed from pretreatment in both data sets were compared to the expression of the given gene in the other treatment cohort. (B) List of the 32 genes that were statistically changed from post treatment to pretreatment in both data sets. (C) Quantitative RT-PCR comparing fold change from pretreatment at twelve weeks following DAA therapy (Black Bars) and twenty-four weeks following IFNα/Ribavirin therapy (White bars). P value represents comparison between both treatments. P<0.05, ***P<0.001, NS = Not significant. N = 8-11patients per group.